Cortexyme (CRTX) Gets a Hold Rating from JMP Securities

In a report released today, Jason Butler from JMP Securities reiterated a Hold rating on Cortexyme (CRTXResearch Report). The company’s shares closed last Tuesday at $4.65, close to its 52-week low of $3.79.

According to TipRanks.com, Butler has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.9% and a 36.8% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, ACADIA Pharmaceuticals, and Aquestive Therapeutics.

Currently, the analyst consensus on Cortexyme is a Moderate Buy with an average price target of $21.00.

See the top stocks recommended by analysts >>

The company has a one-year high of $121.98 and a one-year low of $3.79. Currently, Cortexyme has an average volume of 1.04M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer’s and other neurodegenerative disorders. Its product, COR388, is in clinical trial. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Read More on CRTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed